Aging is a natural process, but many seek to slow it down and improve their quality of life even in old age.
Genetic therapies offer an innovative approach to achieving this goal by repairing genetic damage that causes aging and age-related diseases.

Technologies:

Gene Therapy: This method uses harmless viruses to deliver healthy genes to damaged cells. This approach has been successfully used in gene therapies for rare genetic diseases. An example is gene therapy for SCID, a severe immune disorder, called ADA-SCID. In this treatment, a normal gene is inserted into the patient's white blood cells, enabling them to produce the missing enzyme and strengthening their immune system.
Gene Editing: CRISPR-Cas9 technology enables precise and efficient gene editing. It can be used to correct specific genetic mutations. A notable example is a study by the Salk Institute published in Nature Medicine in 2019, which used CRISPR-Cas9 in mice with progeria (a rapid aging syndrome caused by a mutation in the LMNA gene). Silencing the defective progerin protein improved their health and extended their lifespan by about 25 percent. It is important to emphasize that this is a model of accelerated aging disease in mice, not a halt to normal aging in humans.
Gene Silencing: RNAi technologies allow silencing the activity of harmful genes. This approach may be effective for treating age-related diseases, such as cancer. An example is an experimental treatment for lung cancer, which uses RNAi to silence the activity of a gene that promotes the growth of cancer cells.

iPSC Cell Engineering:

An innovative and fascinating approach is iPSC cell engineering.
This approach causes mature cells to revert to an embryonic stem cell-like state (iPSC) using genetic factors.
These iPSCs can then be directed to differentiate into various types of healthy cells, thereby replacing damaged or aging cells.
An example is early-stage clinical trials where cells derived from iPSCs (e.g., dopamine-producing progenitor cells) were transplanted into the brains of Parkinson's patients. These trials were primarily designed to test safety, and results so far are preliminary and variable.

Research Results:

Early animal studies have shown promising results in certain contexts, but they must be interpreted cautiously before drawing conclusions about humans.
Clinical trials in humans are still in very early stages.
For example, initial trials transplanting patches of heart muscle cells derived from iPSCs in patients with heart failure were primarily intended to confirm safety. In a small number of patients, no side effects related to the transplanted cells were observed, but these are early results requiring further research and do not constitute proof of efficacy.

Treatment of Specific Genes:

Research focuses on specific genes related to aging.
For example, the TP53 gene (the "guardian of the genome") is associated with both aging and cancer, serving as a defense mechanism against tumor development.
In this context, an important caution arises: studies have found that gene editing using CRISPR-Cas9 may confer a survival advantage to cells that already carry a TP53 mutation, thereby enriching the cell population with cells having cancerous potential. Therefore, the integrity of the TP53 gene is considered a key safety issue in the development of gene editing therapies, not an example of a proven treatment in humans.

Challenges:

Developing efficient systems for delivering genes and correcting mutations in all cell types.
Ensuring treatment safety and minimizing side effects.
Developing genetic therapies accessible to all.
Addressing ethical questions regarding the use of these technologies.

Ethical Implications:

Equitable access to treatments: Genetic therapies may be very expensive, potentially limiting access to wealthy individuals only.
There is a need to develop economic models that allow broader access to these treatments.
Misuse of technologies: There is a risk that the use of these technologies could lead to unwanted genetic enhancement, "designer babies," or the creation of a "genetic upper class."
There is a need for an open public discussion on the ethical implications of these technologies and to formulate clear guidelines for their use.

Future of the Field:

The field of genetic therapy for body rejuvenation is expected to develop significantly in the coming years. Many clinical trials are underway and are expected to lead to the development of more effective and safer treatments. However, it is important to remember that these treatments are still in early stages of development and great caution is needed before their use.